cis-Diamminedichloroplatinum plus dimethyl-triazenoimidazole carboxamide as second- and third-line chemotherapy for sarcomas of the female pelvis.
From 1981 to 1984, 20 patients with sarcomas of the female pelvis were treated with dimethyl-triazeno-imidazole carboxamide (DTIC) combined with cis-diamminedichloroplatinum II (DDP) in two sequential studies. Group 1 patients received low-dose (1 mg/kg) DDP plus DTIC; Group 2 patients received high-dose DDP (20 mg/m2 daily for 5 days) plus DTIC. Each regimen was repeated every 4 weeks depending on the patient and bone marrow tolerance. Of the 20 patients, 35% achieved an objective response. Of the 10 group 1 patients, 20% had an objective response (1 CR, 1 PR) both as second-line chemotherapy. For the group 2 patients, 50% (5) have responded (3 CR, 2 PR), one as third-line and 4 as second-line chemotherapy. These results suggest that DTIC plus DDP, especially at the higher dose (20 mg/m2 X 5), is effective chemotherapy for metastatic pelvic sarcomas.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D010386:Pelvic Neoplasms / Q000188:drug therapy*; D012509:Sarcoma / Q000188:drug therapy*
D003606:Dacarbazine; D002945:Cisplatin